Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study.

[1]  D. Royston.  High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.

[2]  W. van Oeveren,et al.  Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. , 1991, The Annals of thoracic surgery.

[3]  W. van Oeveren,et al.  Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.

[4]  V. Boddi,et al.  High-dose aprotinin: hemostatic effects in open heart operations. , 1989, The Annals of thoracic surgery.

[5]  F. Sebening,et al.  Reduction of Homologous Blood Requirement in Cardiac Surgery by Intraoperative Aprotinin Application - Clinical Experience in 152 Cardiac Surgical Patients , 1989, The Thoracic and cardiovascular surgeon.

[6]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[7]  L. Eijsman,et al.  PLATELET PRESERVATION BY APROTININ DURING CARDIOPULMONARY BYPASS , 1988, The Lancet.

[8]  A. Mashiah,et al.  Massive atheromatous emboli to both kidneys: a fatal complication following aortic surgery. , 1988, Journal of Cardiovascular Surgery.

[9]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[10]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.